Teladoc Health (NYSE:TDOC) shares are up on Thursday following the company’s latest earnings report, which highlighted a mix of revenue changes across its segments.The stock is moving higher as the broader market is experiencing a mixed day, with the Nasdaq down 1.57% and the S&P 500 down 0.87%, indicating that the positive movement in Teladoc may be driven by company-specific factors rather than overall market trends.Performance HighlightsTeladoc Health reported a quarterly loss of 14 cents per share, comp ...

Toronto, Ontario--(Newsfile Corp. - February 26, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("Leveljump" or the "Company") announces that, pursuant to the Company's 2022 Equity Incentive Plan, it has granted an aggregate of 2,250,000 incentive stock options (the "Options") to three directors of the Company. Each Option entitles the optionee to acquire one common share of the Company at an exercise price of $0.065 per common share until February 24, 2031. There are no vesting restrictions.About LevelJu ...

Back in September 2025, I wrote an article on LifeMD ( LFMD ) and assigned my first ever Strong Buy rating. I saw LifeMD as an underappreciated telehealth company with a similar business model toI am a software developer by trade who focuses on finding value in the market wherever it may lie. I'm looking mainly in small caps for opportunities that provide asymmetric upside. I'm also interested in generating income through my investments, which leads me to look at high dividend yields that are sustainable. T ...

Teladoc Health (NYSE:TDOC) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsAyush Vyas - Equity Research Associate - Healthcare Technology and Distribution, Healthcare Facilities, and Managed CareChuck Divita - CEODavid Roman - Managing Director and Co-Head Healthcare Business Unit - MedTech and Healthcare ITJailendra Singh - Managing Director - Healthcare Technology, Distribution and CROsMichael Minchak - Head of Investor RelationsRichard Close - Managing Director, Equity Research - ...

Teladoc Health (NYSE:TDOC) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsAyush Vyas - Equity Research Associate - Healthcare Technology and Distribution, Healthcare Facilities, and Managed CareChuck Divita - CEODavid Roman - Managing Director and Co-Head Healthcare Business Unit - MedTech and Healthcare ITJailendra Singh - Managing Director - Healthcare Technology, Distribution and CROsMichael Minchak - Head of Investor RelationsRichard Close - Managing Director, Equity Research - ...

Teladoc Health (NYSE:TDOC) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Speaker17Good afternoon. Thank you for attending today's Teladoc Health Q4 2025 earnings conference call. My name is Tamia, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass this, the conference over ...

Key Takeaways Hims & Hers is expanding into weight care, menopause, testing and new global markets.Hims & Hers is investing in AI, diagnostics and acquisitions to scale its platform.AMWL is refocusing on enterprise clients, cutting costs and targeting positive cash flow by 2026.Digital healthcare continues to evolve across both direct-to-consumer and enterprise channels, with Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL) , popularly known as Amwell, representing two distinct approache ...

Hims & Hers Health, Inc. ( HIMS ) had one chance at making the market like it again, and it missed. While the Q4 numbers looked impressive on paper, the market's reaction suggests that theI’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like my service to revolve ...

Core Insights - Teladoc Health, Inc. is set to release its fourth-quarter 2025 earnings on February 25, 2026, with analysts predicting an earnings per share (EPS) of -$0.19, reflecting a 32.1% improvement from the previous year [1][6] Financial Performance - Revenue for the fourth quarter is projected to be $633.91 million, indicating a slight 1% decline from the same period last year [2][6] - For the full year 2025, revenues are estimated at $2.52 billion, which represents a 1.9% decline from the previous year [4] Segment Analysis - The Integrated Care segment is expected to grow, with membership projected to increase by 9.1% and segment EBITDA anticipated to rise by 20.9% year-over-year [3][6] - Conversely, the BetterHelp segment is facing challenges, with expected revenue declines of 6.2% and a 5% decrease in paying users for the fourth quarter [3] Financial Metrics - The company has a negative price-to-earnings (P/E) ratio of -3.57, indicating a lack of profitability [5] - The price-to-sales ratio stands at 0.32, suggesting that investors are paying $0.32 for every dollar of sales [5] - A debt-to-equity ratio of 0.75 indicates a moderate level of debt, while a current ratio of 2.70 reflects a strong ability to cover short-term liabilities [5]

Core Viewpoint - Hims & Hers Health, Inc. is a prominent telehealth company focused on providing accessible healthcare solutions through its online platform, competing in the expanding digital health market [1] Financial Performance - Hims & Hers reported a revenue of $617.8 million in Q4 2025, reflecting a year-over-year growth of 28.4% driven by an expanding subscriber base of 2.5 million [3] - The company experienced a gross margin contraction of 487 basis points to 71.9%, which has negatively impacted its stock performance despite the strong revenue growth [2][6] - Quarterly earnings per share (EPS) were reported at 7 cents, surpassing the Zacks Consensus Estimate of 2 cents, although lower than the previous year's EPS of 11 cents [4] - For the full year, the EPS was 51 cents, exceeding the Zacks Consensus Estimate by 6.3%, but showing a 3.8% decrease from the prior year [4] Future Guidance - Hims & Hers has projected its 2026 revenue to be between $2.7 billion and $2.9 billion, indicating a positive outlook despite recent challenges [5] - Barclays has set a price target of $25 for Hims, suggesting a potential increase of approximately 57.18% from its current price of $15.91 [2][6] Market Position - The company has a market capitalization of approximately $3.48 billion and a trading volume of 51.27 million shares [5]